News MHRA grants Innovation Passports to three novel drugs The MHRA has awarded Innovation Passports to three drugs that could offer a step forwards in treating lung cancer, Huntington's, and Alzheimer's.
News New diabetes and obesity studies making waves at EASD As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
News Sanofi forges new $8bn pact with Regeneron Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.
News FDA approves Mirum's oral drug for rare disease FOP Mirum's new oral therapy for rare bone disease fibrodysplasia ossificans progressiva (FOP) looks set to challenge Regeneron's intravenous Pasatru.
News FDA greenlights Regeneron drug for rare bone disease Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.
News Lilly, Regeneron among firms chosen for FDA fast plant pilot Eli Lilly, Regeneron, and five other drugmakers will take part in an FDA pilot designed to make it quicker and easier to set up manufacturing plants.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.